Study shows no added benefit of pertuzumab combination in treatment of early breast c

[News]

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

More... (https://www.news-medical.net/news/20181012/Study-shows-no-added-benefit-of-pertuzumab-combination-in-treatment-of-early-breast-cancer.aspx)